Development Cell journal published a new study by Alexey Ryazanov "Germline Quality Control: eEF2K Stands Guard to Eliminate Defective Oocytes"
A new study led by Alexey Ryazanov, a professor of pharmacology at Rutgers Robert Wood Johnson Medical School and member of the Rutgers Cancer Institute of New Jersey, was published in the journal Developmental Cell. Ryazanov’s latest findings demonstrate that the presence of eEF2K weakens healthy cells.
Longevica Pharmaceuticals is a biotech start-up established in 2008 by Dr. Alexey Ryazanov and focused on developing novel chemical inhibitors of eukaryotic elongation factor 2 kinase (eEF2K), a highly promising drug target whose inhibition can achieve multiple beneficial effects ranging from suppressing tumor growth to protecting normal cells from the cytotoxicity of chemotherapeutic agents.
Rostock Group owns 51% of Longevica Pharmaceuticals. In 2014, Rostock Group initiated negotiations with pharmaceutical companies and venture capital to create drugs based on eEF2-kinase.
Topic: Longevica Pharmaceuticals